Cargando…
EGFR突变的晚期非小细胞肺癌的抗PD-1/PD-L1治疗研究进展
The use of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) is the first line treatment for EGFR-mutant advanced non-small cell lung cancer (NSCLC), but drug resistance will be acquired within 1-2 years, and the following treatment efficacy is poor. The invention of programmed...
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
中国肺癌杂志编辑部
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9619349/ https://www.ncbi.nlm.nih.gov/pubmed/36167460 http://dx.doi.org/10.3779/j.issn.1009-3419.2022.101.44 |